Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

440P - Accuracy of risk scoring system to determine delayed chemotherapy induced nausea and vomiting (CINV) in cancer patients

Date

23 Nov 2019

Session

Poster display session

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Jada Harika

Citation

Annals of Oncology (2019) 30 (suppl_9): ix140-ix150. 10.1093/annonc/mdz434

Authors

J. Harika1, V.V. Maka2, A. D3, M. Krishna Murthy4, A. Mandepudi5, P.R. Paibhavi6, S.P. Kanneganti6, S. Vungarala7

Author affiliations

  • 1 Pharm D, MS Ramaiah Memorial Hospital, 560054 - Bangalore/IN
  • 2 Department Of Medical Oncology, M. S. Ramaiah Medical College and Hospitals, 560054 - Bangalore/IN
  • 3 Faculty Of Pharmacy, M. S. Ramaiah University of Applied Sciences, 560054 - Bangalore/IN
  • 4 Faculty Of Pharmacy, Department Of Pharmacy Practice, M. S. Ramaiah University of Applied Sciences, 560054 - Bangalore/IN
  • 5 Pharmacy Ppractice, M. S. Ramaiah University of Applied Sciences, 560054 - Bangalore/IN
  • 6 Pharmacy Practice, M. S. Ramaiah University of Applied Sciences, 560054 - Bangalore/IN
  • 7 Pharmacy Practice, M. S. Ramaiah University of Applied Sciences, 560054 - bangalore/IN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 440P

Background

In this study the risk scoring algorithm is evaluated to see the ability of the scoring systems to accurately identify patients deemed to be high risk for CINV.

Methods

Patients who were receiving first chemotherapy regime at our center were included in the study after due informed consenting and Ethics committee approval. Patients were followed for 5-days after chemotherapy by either in person questioning or telephone call. All patients received standard anti-emetic prophylaxis at discretion of treating physician. Before each cycle of chemotherapy, acute and delayed CINV scoring systems were used to stratify patients into low- and high-risk groups. Logistic regression modelling was then applied to compare the risk for grade 2 or greater CINV between patients considered to be at high and at low risk. The external validity of each system was also assessed using an area under the receiver operating characteristic curve (AUROC) analysis.

Results

CINV outcomes data was collected from 128 patients during 356 cycles of chemotherapy. The incidence of delayed CINV was 76.4% respectively. Major predictors for CINV included younger patient age, earlier cycles of chemotherapy, previous history of morning sickness, and prior emetic episodes after chemotherapy. The delayed scoring system had good predictive accuracy when applied to the external validation sample (delayed—AUROC: 0.75; 95% confidence interval: 0.70 to 0.80). Patients identified by the scoring systems to be at high risk were 3.8 (p = 0.001) times more likely to develop grade 2 or greater delayed CINV.

Conclusions

Our study demonstrates current Patient risk scoring systems are able to accurately identify patients at high risk for delayed CINV and can be used to augment current antiemetic regimes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Vinayak V Maka.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.